Cancer cells with defects in DNA repair are highly susceptible to DNA-damaging agents, but delivery of therapeutic agents into cell nuclei can be challenging. A subset of lupus autoantibodies is associated with nucleolytic activity, and some of these antibodies are capable of nuclear penetration. We hypothesized that such antibodies might have potential as therapeutic agents targeted towards DNA repair-deficient malignancies. We identified the lupus autoantibody 5C6 as a cell-penetrating nucleolytic antibody and found that 5C6 has a differential effect on a matched pair of BRCA2-proficient and deficient DLD1 colon cancer cells. 5C6 selectively induced cH2AX in, and suppressed the growth of, the BRCA2-deficient cells. These findings demonstrate the potential utility of 5C6 in targeted therapy for DNA repair-deficient malignancies and strengthen the rationale for studies of additional lupus autoantibodies in order to identify the best candidates for development as therapeutic agents. In addition, the toxic effect of 5C6 on BRCA2-deficient cells provides further support for the hypothesis that some lupus autoantibodies contribute to the lower risk of specific cancers associated with systemic lupus erythematosus. . A cell-penetrating lupus anti-DNA autoantibody, 3E10, has previously been developed as a vehicle for intracellular delivery of therapeutic cargo molecules, and this approach has proven effective in vitro and in vivo [3] [4] [5] . More recently we made the unexpected discovery that 3E10, by itself, inhibits DNA repair and is synthetically lethal to cancer cells with defects in DNA repair due to BRCA2-deficiency 6 . An emerging area of investigation into cell-penetrating lupus autoantibodies now focuses on their potential use as targeted therapies for cancer.
S
ystemic lupus erythematosus (SLE) is an autoimmune disease in which inappropriate production of autoantibodies results in widespread inflammation and organ dysfunction 1 . A small percentage of lupus autoantibodies penetrate into the nuclei of living cells, and these antibodies have potential utility in molecular therapy 2 . A cell-penetrating lupus anti-DNA autoantibody, 3E10, has previously been developed as a vehicle for intracellular delivery of therapeutic cargo molecules, and this approach has proven effective in vitro and in vivo [3] [4] [5] . More recently we made the unexpected discovery that 3E10, by itself, inhibits DNA repair and is synthetically lethal to cancer cells with defects in DNA repair due to BRCA2-deficiency 6 . An emerging area of investigation into cell-penetrating lupus autoantibodies now focuses on their potential use as targeted therapies for cancer.
Development of tumor-selective therapies is a critical goal in cancer research. Many cancer cells harbor deficiencies in DNA repair and are more sensitive to DNA damage than normal cells 7 , and agents that localize to cell nuclei and inhibit DNA repair or damage DNA therefore have potential as targeted therapies for DNA repair-deficient malignancies. Effective delivery of therapeutic agents to cell nuclei is challenging, but the subset of naturally occurring lupus autoantibodies that penetrate into cell nuclei may be well suited to this role. Based on our discovery that 3E10 inhibits DNA repair and is toxic to BRCA2-deficient cells, we hypothesized that additional lupus autoantibodies may have similar potential for use as targeted cancer therapies.
Importantly, while 3E10 does not appear to directly damage DNA, cell-penetrating nucleolytic lupus autoantibodies have been previously reported 8, 9 . The ability of these antibodies to directly localize into cell nuclei and to potentially induce DNA damage makes them intriguing candidates for development as targeted therapies for DNA repair-deficient malignancies. To the best of our knowledge the impact of a cell-penetrating nucleolytic lupus autoantibody on cells with defects in DNA repair has not been previously tested. We therefore set out to identify a cell-penetrating nucleolytic lupus autoantibody and test its effects on a matched pair of BRCA2-proficient and deficient DLD1 colon cancer cells.
Results

5C6 is a nucleolytic lupus autoantibody.
We screened a panel of lupus anti-DNA antibodies for nucleolytic activity in order to identify a candidate for testing on the BRCA2-deficient cells. Anti-DNA autoantibodies produced by hybridomas generated from the MRL-mpj/lpr mouse model of SLE 10 were incubated with DNA in vitro, and most did not significantly impact the integrity of the DNA (not shown). The IgG2a-k antibody 5C6, however, was found to be associated with significant degradation of both single and double-stranded DNA. When incubated with M13mp18 single-stranded DNA, 5C6 catalyzed degradation of the single-stranded DNA in a time and dose-dependent manner, with near complete degradation of the single-stranded DNA by 10 minutes at doses of 1.25 mM and higher ( Fig. 1A-D) . When incubated with double-stranded plasmid DNA (pBluescript) 5C6 similarly catalyzed a time-dependent degradation of the plasmid DNA (Fig. 1E-F) . These data indicated that 5C6 is associated with nucleolytic activity, and we therefore proceeded to test the effects of 5C6 on cells.
5C6 penetrates into cell nuclei. We first sought to confirm that 5C6 penetrates into cell nuclei. DLD1 colon cancer cells were treated with control media or media containing 5C6. Cells were then washed, fixed, and immunostained for murine IgG. Propidium iodide (PI) counterstaining allowed direct visualization of cell nuclei, and overlay of anti-IgG and PI fluorescent images confirmed nuclear localization by 5C6 in the DLD1 cells (Fig. 2 ).
5C6 has a differential impact on BRCA2-proficient and BRCA2-deficient DLD1 cells. The effect of 5C6 on the matched pair of BRCA2-proficient (BRCA21) and BRCA2-deficient (BRCA2-) DLD1 cells was assessed. Cells were treated with control media or media containing 10 mM 5C6 for one hour, followed by evaluation of the percentage of cells positive for cH2AX (a marker of DNA doublestrand breaks) by immunofluorescence. 5C6 did not increase the percentage of cH2AX-positive BRCA21 cells but did increase the percentage of cH2AX-positive BRCA2-cells approximately 5-fold compared to control cells (2.3% versus 10.3%; p50.03) (Fig. 3A , B, and C). The observed increase in percentage of cH2AX-positive BRCA2-cells after treatment with 5C6 may reflect direct DNA damage induced by 5C6, and the differential impact of 5C6 on cH2AX expression in the BRCA21 and BRCA2-cells suggests that defective DNA repair in the BRCA2-cells makes them more susceptible to the effects of the 5C6 nucleolytic antibody.
5C6 selectively suppresses the growth of the BRCA2-DLD1 cells.
To confirm that 5C6 is more toxic to BRCA2-than BRCA21 cells, we tested the effect of 5C6 on the proliferation of BRCA21 and BRCA2-DLD1 cells growing as subconfluent monolayers. BRCA21 and BRCA2-DLD1 cells were treated with control media or media containing 10 mM 5C6. Four days later total viable cell counts were determined. 5C6 did not significantly inhibit the growth of the BRCA21 cells (percent growth inhibition of 2.8% 6 9). However, 5C6 significantly impaired the growth of the BRCA2-cells (percent growth inhibition of 41% 6 8) (Fig. 3D) . These results are consistent with our finding that 5C6 selectively induced an increase in cH2AX in BRCA2-cells and demonstrate that 5C6 is more toxic to BRCA2-than BRCA21 cells.
5C6 induces senescence in the BRCA2-deficient DLD1 cells. To investigate the mechanism by which 5C6 suppresses the growth of BRCA2-DLD1 cells we examined the effect of 5C6 on membrane integrity as a marker for apoptosis or necrosis. BRCA2-DLD1 cells were treated with control or 10 mM 5C6 and then treated with propidium iodide (PI). No significant increase in the percentage of PI-positive cells in the presence of 5C6 relative to control media was observed (Fig. 4A) , which suggests that neither apoptosis nor necrosis are the primary mechanisms responsible for the effect of 5C6 on BRCA2-cells. We therefore proceeded to test the effect of 5C6 on induction of cell senescence by examining the relative expression of b-galactosidase (b-gal) in cells treated with 5C6. As shown in Fig. 4B -D, 5C6 yielded a significant and dose dependent increase in b-gal expression in the BRCA2-DLD1 cells, which suggests that 5C6 suppresses the growth of the cells by inducing senescence. At dose of 6.6 mM 5C6 increased the percentage of bgal-positive cells to 39.3% 6 1.8 compared to 16.3% 6 1.3 in cells treated with control media.
Discussion
We have shown that a cell-penetrating nucleolytic lupus autoantibody, 5C6, has a differential effect on BRCA21 and BRCA2-DLD1 cells. Specifically, 5C6 induces cH2AX in BRCA2-but not BRCA21 cells and selectively suppresses the growth of the BRCA2-cells.
Mechanistically, 5C6 appears to induce senescence in the BRCA2-cells. Senescence is a well-known response to DNA damage, and DNA damaging agents, including many chemotherapeutics, induce senescence after prolonged exposure [11] [12] [13] . Taken together, the observations listed above provide strong support for the hypothesis that 5C6 penetrates cell nuclei and damages DNA, and that cells with preexisting defects in DNA repair due to BRCA2-deficiency are more sensitive to this damage than cells with intact DNA repair.
We previously found that the cell-penetrating lupus anti-DNA antibody 3E10 inhibits DNA repair and is selectively toxic to BRCA2-cancer cells 6 , which revealed the possibility of using select lupus antibodies as targeted cancer therapies. However, a key question remained regarding whether the effect of 3E10 on BRCA2-cancer cells was a unique phenomenon or if there are other lupus autoantibodies that have similar or even greater potential for use in cancer therapy. We have now answered this question by showing that the nucleolytic lupus autoantibody 5C6 also has a selective effect on BRCA2-deficient cancer cells.
The finding that 5C6 has a selective impact on BRCA2-cells may also provide further insight into the unusual cancer risk profile associated with SLE. SLE is associated with an overall increased risk of malignancy, but lower than expected rates of tumors associated with defects in BRCA2 such as breast, ovarian, and prostate cancers [14] [15] [16] . The pathophysiology underlying this risk profile is unknown and is likely multifactorial 17, 18 . We previously suggested that cell-penetrating lupus autoantibodies such as 3E10 that inhibit DNA repair might contribute to this phenomenon by suppressing growth of BRCA2-cells 6 , and our present findings now raise the possibility that nucleolytic lupus autoantibodies may also contribute to inhibiting the growth of BRCA2-associated tumors in patients with SLE. Additional epidemiologic and laboratory studies are needed before any definitive conclusions may be drawn in this regard.
The primary significance of this work is in providing proof of principle to support additional studies into the application of nucleo- (A): 5C6 does not appear to induce apoptosis or necrosis of BRCA2-DLD1 cells. Cells were treated with control media or media containing 10 mM 5C6, and cell membrane integrity was then examined by visualization of PI uptake. No difference in PI uptake was observed between the cells treated with control or 5C6, suggesting that apoptosis or necrosis are not the primary mechanisms by which 5C6 is toxic to the BRCA2-cells. lytic lupus autoantibodies as targeted therapies for DNA repair-deficient malignancies. A wide range of human malignancies harbor deficiencies in DNA repair 7 , and this therapeutic strategy therefore has potential for applications in the treatment of numerous tumors. The findings presented herein also strengthen the rationale for continuing the search for lupus autoantibodies that may have even greater and more selective effects on cancer cells. Given the diversity of autoantibodies associated with SLE 19 we are confident that additional lupus autoantibodies with therapeutic potential await discovery.
Methods
Hybridomas and cell lines. A panel of hybridomas, including the 5C6 hybridoma, was previously generated from the MRL-mpj/lpr lupus mouse model and DNA binding activity was evaluated 10, 20 . Hybridomas were maintained in serum free hybridoma media (BD Cell MAb medium; BD Biosciences, San Jose, CA) supplemented with 2 mM L-glutamine (Life Technologies, Carlsbad, CA). Antibodies were harvested in hybridoma supernatants and exchange-dialyzed into appropriate media. BRCA21 and BRCA2-DLD1 colon cancer cells (Horizon Discovery Ltd, Cambridge, UK) were grown in RPMI 1640 (Life Technologies) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, Saint Louis, MO).
Cell-penetration assays. DLD1 cells grown on glass coverslips were treated with control buffer or 3.3 mM 5C6 for 1.5 hours. Cells were then washed with PBS, fixed with chilled 100% ethanol for 5 minutes, washed again with PBS, and then probed with Alexa488-conjugated goat anti-mouse IgG antibody overnight at 4uC (Cell Signaling, Danvers, MA). To counterstain the nucleus, PI at 1 mg/ml was added to the cells for 30 minutes. Nuclear penetration by the antibodies was then imaged using an EVOS fl digital fluorescence microscope (Advanced Microscopy Group, Bothell, WA) using green fluorescent protein (GFP) filter (403 magnification; Life Technologies).
cH2AX assays. BRCA21 and BRCA2-DLD1 cells were treated with control media or media containing 10 mM 5C6 for one hour. Cells were then washed with PBS, fixed with chilled 100% ethanol for 5 minutes, washed again with PBS, blocked with 1% BSA/ PBS for 45 minutes and then probed with Alexa488-conjugated anti-cH2AX antibody overnight at 4uC (Cell Signaling). Fluorescent signal corresponding to cH2AX was then imaged using an EVOS fl digital fluorescence microscope using a GFP filter.
Catalytic assays. For single-stranded plasmid DNA assays, single-stranded M13mp18 DNA (New England Biolabs, Ipswich, MA) was incubated with 0-2.5 mM 5C6 for 0-60 minutes in binding buffer (50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl 2 ). The reaction was terminated by the addition of 1% SDS. Samples were boiled and then run on 1% agarose gels and stained with SYBR Gold (Life Technologies) for 30 minutes. The proportion of DNA remaining after treatment relative to untreated M13mp18 DNA was then calculated by band densitometry using ImageJ (National Institutes of Health, Bethesda, MA). pBluescript (Agilent Technologies, Englewood, CO) was used in double-stranded plasmid DNA assays by incubating with 6.6 mM 5C6 for 0-24 hours in binding buffer at 37uC. Samples were then boiled, and DNA conformations were visualized on 1% agarose gels with ethidium bromide. The proportion of DNA remaining after treatment relative to untreated pBluescript DNA was then calculated by band densitometry using ImageJ.
Cell growth assays. BRCA21 and BRCA2-DLD1 cells were plated in 48 well plates at 1 3 10 4 and allowed to adhere overnight. The cells were then treated with control media or media containing 10 mM 5C6. Cell counts were determined four days later by trypan blue extrusion. Percent growth inhibition was then calculated by comparing the total number of viable cells treated with 5C6 relative to cells treated with control media.
Propidium iodide uptake. BRCA2-DLD1 cells were plated in 96 well plates at 3 3 10 4 and allowed to adhere overnight. The cells were then treated with control media or media containing 10 mM 5C6 overnight at 37uC. Antibody was then removed and cells were stained with 1 mg/ml PI for 15 minutes at room temperature. Cells were then imaged for PI uptake using an EVOS fl digital fluorescence microscope using an RFP filter.
Cellular senescence assay. BRCA2-DLD1 cells were plated in 12 well plates at 2 3 10 4 and allowed adhere overnight. The cells were then treated with media containing 0-6.6 mM 5C6. Cells were incubated at 37uC for 4 days. The Senescence-bGal Staining Kit (Cell Signaling Technology) was used for b-gal staining. After treatment cells were washed, fixed and stained for the presence of b-gal at pH 6.0. Cells were then imaged (Olympus IX70, Tokyo, Japan) and percentage of b-gal positive cells calculated.
Statistics. P values were determined by two-tailed Student's t-test.
